These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
140 related items for PubMed ID: 39127115
1. Exploring the effect and mechanism of Hippophae rhamnoides L. triterpenoid acids on improving NAFLD based on network pharmacology and experimental validation in vivo and in vitro. Ren L, Wang R, Wang Y, Tie F, Dong Q, Wang H, Hu N. J Ethnopharmacol; 2024 Dec 05; 335():118657. PubMed ID: 39127115 [Abstract] [Full Text] [Related]
6. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor. Liu M, Zhang G, Wu S, Song M, Wang J, Cai W, Mi S, Liu C. J Ethnopharmacol; 2020 Jun 12; 255():112776. PubMed ID: 32205261 [Abstract] [Full Text] [Related]
7. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Quan HY, Kim DY, Kim SJ, Jo HK, Kim GW, Chung SH. Biochem Pharmacol; 2013 May 01; 85(9):1330-40. PubMed ID: 23435355 [Abstract] [Full Text] [Related]
8. Study on the action mechanism of the Polygonum perfoliatum L. on non-alcoholic fatty liver disease, based on network pharmacology and experimental validation. Liu G, Yang L, Tang Y, Lin J, Wang F, Shen J, Chang B, Kong X. J Ethnopharmacol; 2024 Jan 30; 319(Pt 3):117330. PubMed ID: 37863399 [Abstract] [Full Text] [Related]
9. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway. Kim DE, Chang BY, Jeon BM, Baek JI, Kim SC, Kim SY. Int J Mol Sci; 2020 Jun 25; 21(12):. PubMed ID: 32630596 [Abstract] [Full Text] [Related]
10. BI-7273, a BRD9 inhibitor, reduces lipid accumulation by downregulating the AKT/mTOR/SREBP1 signaling pathway. Li Y, He Q, Chen S, Dli H, Zhao J, Sun X, Yang P, Mao Q, Xia H. Biochem Pharmacol; 2024 Aug 25; 226():116412. PubMed ID: 38971334 [Abstract] [Full Text] [Related]
13. Comprehensive pharmacological and experimental study of Ginsenoside Re as a potential therapeutic agent for non-alcoholic fatty liver disease. Zhang J, Duan M, Wu S, Jiang S, Hu S, Chen W, Zhang J, Quan H, Yang W, Wang C, Global Obesity Collaborative. Biomed Pharmacother; 2024 Aug 25; 177():116955. PubMed ID: 38906030 [Abstract] [Full Text] [Related]
16. Extract of Silphium perfoliatum L. improve lipid accumulation in NAFLD mice by regulating AMPK/FXR signaling pathway. Xu J, Jia W, Zhang G, Liu L, Wang L, Wu D, Tao J, Yue H, Zhang D, Zhao X. J Ethnopharmacol; 2024 Jun 12; 327():118054. PubMed ID: 38484950 [Abstract] [Full Text] [Related]
17. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice. Lee MR, Yang HJ, Park KI, Ma JY. Phytomedicine; 2019 Mar 01; 55():14-22. PubMed ID: 30668424 [Abstract] [Full Text] [Related]
18. Huangqin-Huanglian Decoction Protects Liver against Non-alcoholic Fatty Liver Disease in High Fat-diet Mice. Yang H, Wei D, Zhang Y, Jian W. Endocr Metab Immune Disord Drug Targets; 2024 Mar 01; 24(6):691-708. PubMed ID: 37859322 [Abstract] [Full Text] [Related]